Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Med Oral Patol Oral Cir Bucal ; 28(5): e450-e456, 2023 Sep 01.
Article in English | MEDLINE | ID: mdl-37622431

ABSTRACT

BACKGROUND: Studies try to explain the hypothesis that maternal periodontitis may be associated with preterm birth. MATERIAL AND METHODS: This is a case-control study with 120, 40 cases (gestational age <37 weeks) and 80 controls (gestational age ≥37 weeks), that were submitted to the clinical periodontal examination and subgingival biofilm collection. Bacterial DNA of subgingival biofilm was performed and processed by qPCR. RESULTS: Periodontitis was statistically significant in the Case group (35%) when compared to the Control group (11.2%) and Gingival Bleeding Index (GBI), sites with PS ≥ 4mm and sites with CAL ≥ 5mm were statistically higher in the Case group (p < 0.05). The proportions of Pi (p = 0.026) and Fn (p = 0.041) of subgingival biofilm were higher in the Case group. A greater number of sites with PS ≥ 4mm (r = -0.202; p = 0.026) and CAL ≥ 5mm (r = -0.322; p < 0.001) were correlated to lower gestational age. CONCLUSIONS: Periodontitis, preterm delivery, and/or low birth weight may have a possible relationship based on clinical parameters and the ratio of Pi and Fn at periodontal sites.


Subject(s)
Periodontitis , Premature Birth , Infant, Newborn , Humans , Female , Infant , Fusobacterium nucleatum , Prevotella , Case-Control Studies , Periodontitis/complications
2.
Genet Mol Res ; 13(4): 9077-85, 2014 Oct 31.
Article in English | MEDLINE | ID: mdl-25366799

ABSTRACT

We examined the prevalence of human papillomavirus (HPV) infection in Brazilian women with cervical intraepithelial neoplasia. Our goal was to identify the types of HPV and their association with risk factors. This prospective cross-sectional study included 97 samples collected from women aged 14-79 years at the public health units of gynecological care in São Luís, MA, Brazil. HPV detection was performed by nested polymerase chain reaction and sequence analysis. The study patients completed a structured questionnaire to provide information regarding their socio-demographic, clinical, and behavioral status. HPV prevalence was found to be 80.4%, with 17 virus types detected, including HPV 16, 18, 58, 6, and 11. Significant associations between HPV infection and age and frequency of doctor visits were identified. The study findings indicate the significance of age and low frequency of visits to the gynecologist as risk factors for genital HPV infection, suggesting that HPV infection-derived cervical cancer could be prevented through orientation programs for women, which include sex education and information regarding screening tests. We also found an increased prevalence of high-risk HPV serotypes in cervical lesions, which reveals an association between cervical lesions and high-risk HPV.


Subject(s)
Papillomaviridae/physiology , Papillomavirus Infections/virology , Uterine Cervical Dysplasia/virology , Uterine Cervical Neoplasms/virology , Adolescent , Adult , Age Factors , Aged , Brazil/epidemiology , Cross-Sectional Studies , DNA, Viral/chemistry , DNA, Viral/genetics , Female , Host-Pathogen Interactions , Humans , Middle Aged , Papillomaviridae/classification , Papillomaviridae/genetics , Papillomavirus Infections/diagnosis , Papillomavirus Infections/epidemiology , Polymerase Chain Reaction , Prevalence , Prospective Studies , Risk Factors , Sequence Analysis, DNA , Species Specificity , Surveys and Questionnaires , Young Adult
3.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;47(11): 1008-1015, 11/2014. tab, graf
Article in English | LILACS | ID: lil-723902

ABSTRACT

The CYP2D6 enzyme is crucial for the metabolism of tamoxifen. The CYP2D6 gene is highly polymorphic, and individuals can be extensive, intermediate, or poor tamoxifen metabolizers. The aim of this study was to determine the frequencies of the CYP2D6 *3, *4, and *10 alleles in women with breast cancer who were treated with tamoxifen and analyze the association of enzyme activity with prognostic factors and disease-free survival. We observed a high frequency of CYP2D6 *10, with an allelic frequency of 0.14 (14.4%). The *3 allele was not present in the studied population, and *4 had an allelic frequency of 0.13 (13.8%). We conclude that patients with reduced CYP2D6 activity did not present worse tumor characteristics or decreased disease-free survival than women with normal enzyme activity, as the difference was not statistically significant. We also observed a high frequency of CYP2D6 *10, which had not been previously described in this specific population. This study is the first in north-northeastern Brazil that aimed to contribute to the knowledge of the Brazilian regional profile for CYP2D6 polymorphisms and their phenotypes. These findings add to the knowledge of the distribution of different polymorphic CYP2D6 alleles and the potential role of CYP2D6 genotyping in clinical practice prior to choosing therapeutic protocols.


Subject(s)
Adult , Female , Humans , Middle Aged , Young Adult , Adenocarcinoma/genetics , Breast Neoplasms/genetics , /genetics , Gene Frequency , Alleles , Adenocarcinoma/diagnosis , Adenocarcinoma/drug therapy , Adenocarcinoma/epidemiology , Antineoplastic Agents, Hormonal/therapeutic use , Brazil/epidemiology , Breast Neoplasms/diagnosis , Breast Neoplasms/drug therapy , Breast Neoplasms/epidemiology , Cross-Sectional Studies , /classification , Disease-Free Survival , Genotype , Neoplasm Staging , Phenotype , Prognosis , Polymorphism, Genetic/genetics , Tamoxifen/therapeutic use
4.
Braz J Med Biol Res ; 47(11): 1008-15, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25296365

ABSTRACT

The CYP2D6 enzyme is crucial for the metabolism of tamoxifen. The CYP2D6 gene is highly polymorphic, and individuals can be extensive, intermediate, or poor tamoxifen metabolizers. The aim of this study was to determine the frequencies of the CYP2D6 *3, *4, and *10 alleles in women with breast cancer who were treated with tamoxifen and analyze the association of enzyme activity with prognostic factors and disease-free survival. We observed a high frequency of CYP2D6 *10, with an allelic frequency of 0.14 (14.4%). The *3 allele was not present in the studied population, and *4 had an allelic frequency of 0.13 (13.8%). We conclude that patients with reduced CYP2D6 activity did not present worse tumor characteristics or decreased disease-free survival than women with normal enzyme activity, as the difference was not statistically significant. We also observed a high frequency of CYP2D6 *10, which had not been previously described in this specific population. This study is the first in north-northeastern Brazil that aimed to contribute to the knowledge of the Brazilian regional profile for CYP2D6 polymorphisms and their phenotypes. These findings add to the knowledge of the distribution of different polymorphic CYP2D6 alleles and the potential role of CYP2D6 genotyping in clinical practice prior to choosing therapeutic protocols.


Subject(s)
Adenocarcinoma/genetics , Breast Neoplasms/genetics , Cytochrome P-450 CYP2D6/genetics , Gene Frequency , Adenocarcinoma/diagnosis , Adenocarcinoma/drug therapy , Adenocarcinoma/epidemiology , Adult , Alleles , Antineoplastic Agents, Hormonal/therapeutic use , Brazil/epidemiology , Breast Neoplasms/diagnosis , Breast Neoplasms/drug therapy , Breast Neoplasms/epidemiology , Cross-Sectional Studies , Cytochrome P-450 CYP2D6/classification , Disease-Free Survival , Female , Genotype , Humans , Middle Aged , Neoplasm Staging , Phenotype , Polymorphism, Genetic/genetics , Prognosis , Tamoxifen/therapeutic use , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL